Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial

Acta Psychiatrica Scandinavica
M O HuttunenV Raitasuo

Abstract

A double-blind, randomized, multi-center, parallel-group study was conducted in Finland to compare the efficacy and safety of risperidone with zuclopenthixol in patients with acute exacerbations of schizophrenia or schizophreniform disorder. Ninety-eight patients were randomly assigned to treatment with risperidone (n = 48) or zuclopenthixol (n = 50), in variable doses, for 6 weeks. The mean daily doses of risperidone and zuclopenthixol at the end of the trial were 8 mg and 38 mg respectively. Efficacy was assessed throughout by the Positive and Negative Syndrome Scale for schizophrenia and Clinical Global Impression. Safety assessments included the Extrapyramidal Symptom Rating Scale, UKU Side-Effect Rating Scale, vital signs, body weight and laboratory screening. The results indicate that risperidone is at least as effective as zuclopenthixol for the treatment of acute schizophrenic episodes, with a trend towards greater improvement in the overall severity of symptoms. The onset of action was significantly shorter with risperidone than with zuclopenthixol. Although the general tolerability of the two drugs was comparable, fewer patients experienced extrapyramidal symptoms with risperidone, so that significantly fewer risperid...Continue Reading

References

May 1, 1977·Archives of General Psychiatry·H G HanleyD X Freedman
Sep 1, 1990·Pharmacopsychiatry·Y G GeldersP A Janssen
Jan 1, 1988·Psychopharmacology Series·D E Casey, G A Keepers
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Apr 1, 1982·Archives of General Psychiatry·J M Kane, J M Smith
Jun 1, 1981·Archives of General Psychiatry·L E DeLisiR J Wyatt
Jan 1, 1994·Acta Psychiatrica Scandinavica. Supplementum·S R Marder

❮ Previous
Next ❯

Citations

Dec 5, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·E MohrP P De Deyn
Mar 20, 2004·Irish Journal of Medical Science·J V Lucey, S E Libretto
Jan 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·G BondolfiH Dufour
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frank-Gerald Pajonk
Dec 31, 2002·Psychoneuroendocrinology·R Tandon, M D Jibson
Sep 1, 1998·European Psychiatry : the Journal of the Association of European Psychiatrists·P BechA Claus
Jul 7, 2007·Journal of Biopharmaceutical Statistics·Geert MolenberghsTony Vangeneugden
Jul 9, 2008·Journal of Biopharmaceutical Statistics·Tony VangeneugdenHelena Geys
Jul 19, 2001·International Clinical Psychopharmacology·S KasperUNKNOWN RODOS Investigator Group
Jul 19, 2001·International Clinical Psychopharmacology·S KasperUNKNOWN RODOS Investigator Group
Dec 1, 2005·International Clinical Psychopharmacology·Jean-Michel AzorinHenrik Loft
Jan 24, 2007·BMC Psychiatry·Thomas J RaedlerKlaus Wiedemann
Feb 26, 2004·Controlled Clinical Trials·Tony VangeneugdenGeert Molenberghs
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Jul 22, 2004·Current Medical Research and Opinion·Joyce G SmallJeffrey J Kellams
Feb 28, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·H J Möller
Sep 22, 2005·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Apr 7, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Stephan RuhrmannMichael Philipp
May 20, 2006·The British Journal of Mathematical and Statistical Psychology·Annouschka LaenenGeert Molenberghs
Aug 26, 2006·Schizophrenia Research·Brendan P MurphyPatrick D McGorry
Apr 10, 2003·The Psychiatric Clinics of North America·Robin Emsley, Piet Oosthuizen
Jul 28, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Hans-Jürgen Möller
May 5, 2000·The Cochrane Database of Systematic Reviews·E KennedyS Gilbody
Aug 29, 2013·The Cochrane Database of Systematic Reviews·Lorna DonnellyClive E Adams
Mar 30, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·C Stanniland, D Taylor
Feb 24, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·T Wetterling
Apr 20, 2012·The Cochrane Database of Systematic Reviews·Kaushadh JayakodyShalmini Gunadasa
Jul 12, 2013·Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry·Kazunori SaitohMasami Shibukawa
Apr 19, 2000·Journal of Clinical Psychopharmacology·P Mohr, P Czobor
Jun 14, 2003·The Cochrane Database of Systematic Reviews·R H HunterF Song
Aug 29, 2006·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Gabriel RubioCecilio Alamo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.